Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mogamulizumab - Kyowa Kirin

Drug Profile

Mogamulizumab - Kyowa Kirin

Alternative Names: AMG-761; KW-0761; Mogamulizumab-kpkc; Poteligeo

Latest Information Update: 15 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyowa Hakko
  • Developer Amgen; Bristol-Myers Squibb; Kagoshima University Dental School; Kyowa Hakko; Kyowa Hakko Kirin; Kyowa Kirin; Ono Pharmaceutical
  • Class Antiasthmatics; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CCR4 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma; Adult T-cell leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Adult T-cell leukaemia-lymphoma; Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma
  • Registered Mycosis fungoides; Sezary syndrome
  • Phase III Spinal cord disorders
  • No development reported Non-small cell lung cancer
  • Discontinued Asthma; Hypersensitivity; Solid tumours

Most Recent Events

  • 30 Sep 2019 Discontinued - Phase-I/II for Solid tumours (Combination therapy with nivolumab, Late-stage disease, Metastatic disease) in USA (IV)
  • 31 May 2019 Updated efficacy data from the phase III MAVORIC trial in Cutaneous T-cell lymphoma (CTCL) presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
  • 26 Nov 2018 Registered for Mycosis fungoides (Second-line therapy or greater) in European Union, Iceland, Norway, and Liechtenstein (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top